BioMarin execs discuss some eye-popping numbers for the price of valrox — but haven't we heard this before?
SAN FRANCISCO — BioMarin got some considerable attention from the Wall Street Journal today with its revelation that CEO JJ Bienaimé has been thinking about charging $2 million to $3 million for the company’s new gene therapy for hemophilia A, valrox, which is the lead drug in the race for a pioneering FDA approval.
It’s an important discussion, and we’re glad to see it play out in the gray lady of Street speak, which has a big reach. But close observers will note that this isn’t a new number. Bienaime and his executive team discussed that very same range back in February during their Q4 call, which we reported on. Maybe others buzzed about it as well.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.